- Home
- BGLC vs BIAF Comparison
BGLC vs BIAF Comparison
Compare BGLC & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- BIAF
- Stock Information
- Founded
- BGLC 2017
- BIAF 2014
- Country
- BGLC Malaysia
- BIAF United States
- Employees
- BGLC N/A
- BIAF N/A
- Industry
- BGLC Medical Specialities
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BGLC Health Care
- BIAF Health Care
- Exchange
- BGLC Nasdaq
- BIAF Nasdaq
- Market Cap
- BGLC 7.8M
- BIAF 6.6M
- IPO Year
- BGLC N/A
- BIAF 2022
- Fundamental
- Price
- BGLC $4.39
- BIAF $1.46
- Analyst Decision
- BGLC
- BIAF Hold
- Analyst Count
- BGLC 0
- BIAF 1
- Target Price
- BGLC N/A
- BIAF N/A
- AVG Volume (30 Days)
- BGLC 126.1K
- BIAF 136.9K
- Earning Date
- BGLC 11-14-2025
- BIAF 11-14-2025
- Dividend Yield
- BGLC N/A
- BIAF N/A
- EPS Growth
- BGLC N/A
- BIAF N/A
- EPS
- BGLC N/A
- BIAF N/A
- Revenue
- BGLC $9,465,006.00
- BIAF $6,776,739.00
- Revenue This Year
- BGLC N/A
- BIAF N/A
- Revenue Next Year
- BGLC N/A
- BIAF $20.04
- P/E Ratio
- BGLC N/A
- BIAF N/A
- Revenue Growth
- BGLC 2.21
- BIAF N/A
- 52 Week Low
- BGLC $2.01
- BIAF $1.25
- 52 Week High
- BGLC $15.60
- BIAF $46.53
- Technical
- Relative Strength Index (RSI)
- BGLC 37.35
- BIAF 34.49
- Support Level
- BGLC $4.35
- BIAF $1.25
- Resistance Level
- BGLC $4.94
- BIAF $1.57
- Average True Range (ATR)
- BGLC 0.28
- BIAF 0.20
- MACD
- BGLC -0.06
- BIAF -0.05
- Stochastic Oscillator
- BGLC 11.24
- BIAF 17.60
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.